Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis ; volume:22 ; number:1 ; day:21 ; month:10 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cancer ; 22, Heft 1 (21.10.2022), 1-8, 12.2022
- Creator
-
Yang, Teng-Kai
Yu, Ya-Fang
Tsai, Chiao-Ling
Li, Hsing-Ju
Yang, Po-Sheng
Huang, Kai-Wen
Cheng, Jason Chia-Hsien
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-10174-6
- URN
-
urn:nbn:de:101:1-2023010709281157280205
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yang, Teng-Kai
- Yu, Ya-Fang
- Tsai, Chiao-Ling
- Li, Hsing-Ju
- Yang, Po-Sheng
- Huang, Kai-Wen
- Cheng, Jason Chia-Hsien
- SpringerLink (Online service)
Other Objects (12)
Targeted therapy, immunotherapy, and chemotherapy for chordoma
Targeted Therapy and Immunotherapy for Melanoma in Japan
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
BCMA-targeted immunotherapy for multiple myeloma
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy
Targeted therapy, immunotherapy, and chemotherapy for chordoma
Targeted Therapy and Immunotherapy for Melanoma in Japan
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
BCMA-targeted immunotherapy for multiple myeloma
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy
Targeted therapy, immunotherapy, and chemotherapy for chordoma
Targeted Therapy and Immunotherapy for Melanoma in Japan
Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation
SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy
Novel targeted therapies and immunotherapy for advanced thyroid cancers
BCMA-targeted immunotherapy for multiple myeloma
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Systemically targeted cancer immunotherapy and gene delivery using transmorphic particles
Oligometastasis and local ablation in the era of systemic targeted and immunotherapy
Genetic heterogeneity and transcriptional plasticity drive resistance during immunotherapy and targeted therapy
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges